EUVIMEDEUVIMED entdecken
Open Access

Gene-based drug therapy for children and youth treated with psychoactive medications

Ruud H J Verstegen, Iris Cohn, Mark E Feldman, Daniel Gorman, Shinya Ito

Paediatrics & Child Health · 13.09.2024 · 29 (5) · 318-323

DOI: 10.1093/pch/pxae029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Paediatrics & Child Health, online erschienen am 13.09.2024. Verfasst von Ruud H J Verstegen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Canadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychoactive medications are increasingly used to treat children and youth with mental health conditions, but individual variations in response highlight the need for precision medicine. Pharmacogenetic (PGx) testing is a key component of precision medicine. The number of commercial pharmacogenetic testing companies promoting PGx, with the promise of achieving individualized and effective treatment of mental health conditions, has grown exponentially in recent years. Scientific evidence supporting the use of PGx to manage mental health conditions is limited, especially for paediatric populations. This practice point outlines steps guiding the use and interpretation of PGx testing for psychoactive medications in clinical settings, along with key supportive resources. Practice guidelines have been developed for variants in pharmacogenes encoding cytochrome P450 drug-metabolizing enzymes (e.g., CYP2C19, CYP2D6, CYP2C9) as one determinant of drug concentrations in blood, which can support both drug choice and dosing strategy for certain anti-psychotics, anti-depressants, and anti-epileptics. Adverse drug reactions to some anti-epileptic drugs (e.g., carbamazepine and phenytoin) have been associated with certain human leukocyte antigen types and variants in DNA polymerase gamma (POLG; valproic acid). Evidence remains limited for genetic variants of drug target proteins, making it challenging to identify patients with altered treatment responses at a therapeutic blood concentration.

Schlagwörter

Stichwörter der Autor:innen

Child and youth mental healthChild psychiatryPharmacogenetic testingPrecision medicine

Autor:innen und Institutionen

  • Canadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.

Zitieren

APA

Verstegen, R. H. J., Cohn, I., Feldman, M. E., Gorman, D., & Ito, S. (2024). Gene-based drug therapy for children and youth treated with psychoactive medications. Paediatrics & Child Health, 29(5), 318-323. https://doi.org/10.1093/pch/pxae029

Vancouver

Verstegen RHJ, Cohn I, Feldman ME, Gorman D, Ito S. Gene-based drug therapy for children and youth treated with psychoactive medications. Paediatrics & Child Health. 2024;29(5):318-323. doi:10.1093/pch/pxae029

BibTeX
@article{Verstegen2024,
  author = {Verstegen, Ruud H J and Cohn, Iris and Feldman, Mark E and Gorman, Daniel and Ito, Shinya},
  title = {Gene-based drug therapy for children and youth treated with psychoactive medications},
  journal = {Paediatrics & Child Health},
  year = {2024},
  volume = {29},
  number = {5},
  pages = {318--323},
  doi = {10.1093/pch/pxae029}
}
Kostenlos starten →